Maze Therapeutics (NASDAQ: MAZE) and eXoZymes (NASDAQ: EXOZ) are two emerging players in the biopharmaceutical field, each targeting specific medical challenges. A financial review highlights how they measure up against each other based on valuation, profitability, earnings, analyst recommendations, and other key factors.
Analyst Ratings Comparison
Current ratings from analysts provide insights into the potential of both companies. Maze Therapeutics holds a consensus price target of $44.50, indicating a potential downside of 1.18%. This suggests that analysts view Maze more favorably than eXoZymes, which has a weaker consensus rating. As analysts assess the future potential of these stocks, Maze’s stronger outlook positions it as a more attractive investment.
Profitability and Earnings Overview
A comparative analysis of earnings and valuation reveals that Maze Therapeutics outperforms eXoZymes in terms of both revenue and earnings per share. While eXoZymes trades at a lower price-to-earnings ratio, indicating a more affordable stock, it has not yet matched Maze’s financial performance. This disparity highlights the challenges eXoZymes faces in establishing its market position.
Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with chronic kidney disease (CKD), cardiovascular diseases, and related metabolic conditions. Utilizing its proprietary Compass platform, Maze identifies genetic variants associated with disease and links them to biological pathways. This innovative approach informs the drug discovery process and clinical trial design.
The company is advancing two lead programs: MZE829 and MZE782. MZE829 is an oral, small molecule inhibitor targeting apolipoprotein L1 (APOL1), aimed at treating patients with APOL1 kidney disease (AKD). This condition affects over one million patients in the United States. Recent Phase 1 clinical trial results for MZE829, which enrolled 111 healthy participants, indicated that the treatment was well tolerated with no severe adverse events reported.
Maze initiated a Phase 2 clinical trial for MZE829 in November 2024, with the first patient expected to be dosed in the first quarter of 2025. The company anticipates reporting proof of concept data in the first quarter of 2026.
The second lead program, MZE782, targets the SLC6A19 solute transporter and aims to help approximately five million CKD patients who currently do not adequately respond to existing therapies. Initial data from the Phase 1 trial of MZE782 is expected in the second half of 2025. In addition to CKD, MZE782 may also benefit patients with phenylketonuria (PKU), a genetic metabolic disease.
Founded in August 2017, Maze Therapeutics has undergone several name changes and is headquartered in South San Francisco, California. The company’s focus on precision medicine and its commitment to addressing genetic drivers of disease set it apart in the competitive biopharmaceutical landscape.
eXoZymes, on the other hand, is a development stage synthetic biochemical company established in April 2019. Based in Monrovia, Nevada, eXoZymes aims to leverage its synthetic biology platform to explore a wide range of molecules and properties found in nature. While the company shows promise, it faces significant competition in the biopharmaceutical sector.
In summary, Maze Therapeutics currently leads in nine of the eleven factors evaluated in the comparison with eXoZymes. As both companies continue to develop their respective pipelines, investors will be closely watching their progress and market strategies in the coming months.
